(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 21 October 2004 (21.10.2004)

PCT

(10) International Publication Number WO 2004/089342 A3

(51) International Patent Classification⁷: 31/4439, 9/28

A61K 9/20.

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,

(21) International Application Number:

PCT/EP2004/050493

(22) International Filing Date: 8 April 2004 (08.04.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

103 17 023.5 03008453.7

11 April 2003 (11.04.2003) DE 11 April 2003 (11.04.2003) EP

- (71) Applicant (for all designated States except US): ALTANA PHARMA AG [DE/DE]; Byk-Gulden-Str. 2, 78467 Konstanz (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DIETRICH, Rango [DE/DE]; Im Tiergarten 16, 78465 Konstanz (DE). NEY, Hartmut [DE/DE]; Peter-Thumb-Str. 46, 78464 Konstanz (DE). HILTL, Simone [DE/DE]; Clara-Schumann-Str. 8, 78464 Konstanz (DE). HAAS, Bernd-Michael [DE/DE]; In der Abtswiese 22, 78479 Reichenau (DE).
- (74) Agent: RUPP, Herbert; c/o Altana Pharma AG, Byk-Gulden-Str. 2, 78467 Konstanz (DE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, F1, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, F1, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAP1 patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

with international search report

(88) Date of publication of the international search report: 10 March 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ORAL PHARMACEUTICAL PREPARATION COMPRISING A PROTON PUMP ANTAGONIST AND A BASIC EXIPIENT

Inten al Application No

PC.

'2004/050493

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K9/20 A61K31/4439 A61K9/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K IPC 7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED	TO BE	RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
X	WO 02/45693 A (BYK GULDEN LOMBERG CHEM FAB; LINDER RUDOLF (DE); NEY HARTMUT (DE); DI) 13 June 2002 (2002-06-13) cited in the application page 44, line 9 - page 46, line 6 examples 27-29 page 40, paragraph 5 page 41, paragraph 2 page 42, paragraph 3 example N	1-26
X Y	DE 199 25 710 A (BYK GULDEN LOMBERG CHEM FAB) 14 December 2000 (2000-12-14) column 3, line 40 - line 63 column 4, line 23 - line 28 column 4, line 60 - line 68 examples column 5, line 18 - line 25	1-16, 22-26 17-21

		-/			
X Furth	er documents are listed in the continuation of box C.	χ Patent family members are liste	d in annex.		
Special categories of cited documents: A* document defining the general state of the art which is not considered to be of particular relevance E* earlier document but published on or after the international filling date L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) O* document referring to an oral disclosure, use, exhibition or other means P* document published prior to the international filling date but later than the priority date claimed		 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family 			
	December 2004	Date of mailing of the international so	earch report		
Name and n	nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Authorized officer Giménez Miralles	, J		

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT					
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
X	WO 00/74654 A (BYK GULDEN LOMBERG CHEM FAB; LINDER RUDOLF (DE); DIETRICH RANGO (DE)) 14 December 2000 (2000-12-14)	1-16, 22-26			
Y	page 6, paragraph 6 - page 7, paragraph 4 examples	17-21			
X	US 2002/045646 A1 (PHILLIPS JEFFREY 0) 18 April 2002 (2002-04-18)	1-16, 22-26			
Y	paragraphs '0036!, '0037!, '0085! - '0090!, '0278!, '0394!, '0398! - '0403!, '0418! - '0432!, '0436! - '0446! Tablet D3, example I table 8	17-21			
P,X	US 2004/028737 A1 (DESHMUKH SATISH RAMACHANDRA ET AL) 12 February 2004 (2004-02-12) examples 3,4	1-16, 22-26			
X	EP 1 222 922 A (EISAI CO LTD) 17 July 2002 (2002-07-17)	1-16, 22-26			
Υ	examples 4-8; table 2	17-21			
Χ	US 6 299 904 B1 (SHIMIZU TOSHIHIRO ET AL) 9 October 2001 (2001-10-09)	1-16, 22-26			
Υ	column 6, line 65 - column 7, line 34 example 5	17-21			
Х	US 4 786 505 A (ODA MINORU ET AL) 22 November 1988 (1988-11-22)	1-16, 22-26			
Υ	examples 9,10	17-21			
X	WO 98/50019 A (CHEN JIVN REN ; SAGE PHARMACEUTICALS INC (US)) 12 November 1998 (1998-11-12)	1-16, 22-26			
Υ	examples	17–21			
X	WO 00/78284 A (LAHAV RAFFAEL ; AZOULAY VALERIE (IL); DEXCEL LTD (IL))	1-16, 22-26			
Υ	28 December 2000 (2000-12-28) examples 1,4,10,13	17-21			
i					

INTERNATIONAL SEARCH REPORT

ational application No. PCT/EP2004/050493

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)				
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:				
2. X Claims Nos.: 1-26 partly because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:				
an extent that no meaningful International Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210				
2 Claima Nas .				
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).				
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)				
This International Searching Authority found multiple inventions in this international application, as follows:				
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.				
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.				
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:				
4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:				
Remark on Protest The additional search fees were accompanied by the applicant's protest.				
No protest accompanied the payment of additional search fees.				

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.: 1-26 partly

Present independent claim 1 relates to an extremely large number of possible oral dosage forms, namely all those comprising: 1) a reversible PPI ("proton pump antagonist" or APA), and 2) a basic excipient, with no restriction or limitation, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such dosage forms, namely film-coated immediate release tablets comprising soraprazan (as defined in claim 18) and a basic compound as defined in claims 15 and 16. Other possibilities are not sufficiently disclosed in the application. In particular, it is not proved that the stabilising effect is also achieved for other APAs different from soraprazan. The area covered by the claims is broader than justified by the extent of the disclosure. It follows that the claims so lack support, and/or the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. It is the same for independent claims 22 and 23.

Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the dosage form by reference to the result to be achieved, expressed in terms of parameters (disintegration rate; see claims 3, 6-10 and 23-25), which only amounts to claiming the technical problem to be solved instead of claiming the relevant technical features which amount to its solution. This lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to claim 1 taken in combination with claims 5, 15 and 16, and 18, as interpreted in connection with the description and the examples.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

ormation on patent family members

interi

PC:

as application No

2004/050493

Patent document Publication Patent family Publication cited in search report member(s) date WO 0245693 Α 13-06-2002 AU 1607302 A 18-06-2002 BR 0115987 A 23-12-2003 CA 2430828 A1 13-06-2002 CZ 20031881 A3 14-04-2004 EE 200300235 A 15-08-2003 WO 0245693 A1 13-06-2002 EP 1341527 A1 10-09-2003 HU 0400566 A2 28-06-2004 JP 2004514736 20-05-2004 NO 20032593 A 05-08-2003 US 2004058896 A1 25-03-2004 DE 19925710 Α 14-12-2000 DE 19925710 A1 14-12-2000 WO 0074654 Α 14-12-2000 ΑU 775995 B2 19-08-2004 AU 5074100 A 28-12-2000 BG 106165 A 30-09-2002 BR 0011347 A 19-03-2002 CA 2376202 A1 14-12-2000 CN 1361683 T 31-07-2002 CZ 20014405 A3 17-04-2002 200100660 A EE 15-04-2003 WO 0074654 A1 14-12-2000 EP 1187601 A1 20-03-2002 HR 20020006 A1 30-04-2003 HU 0201637 A2 28-11-2002 JP 2003501377 T 14-01-2003 MX PA01012659 A 04-09-2003 NO 20015980 A 23-01-2002 PL 352882 A1 22-09-2003 SK 18022001 A3 04-04-2002 TR 200103527 T2 22-04-2002 ZA 200110000 A 03-10-2002 18-04-2002 US 2002045646 A1 US 6489346 B1 03-12-2002 US 5840737 A 24-11-1998 BR 0210971 A 24-08-2004 CA 2453117 A1 06-02-2003 EP-1414452 A1 06-05-2004 JP 2004521955 22-07-2004 WO 03009846 A1 06-02-2003 US 2003191159 A1 09-10-2003 US 2004048896 A1 11-03-2004 US 2004171646 A1 02-09-2004 AU 3276701 A 24-07-2001 BR 0107565 A 11-02-2003 CA 2396159 A1 19-07-2001 EP 1246622 A1 09-10-2002 EP 1430895 A1 23-06-2004 JP 2003519656 T 24-06-2003 MX PA02006780 A 06-10-2003 NO 20023313 A 30-08-2002 PL 357144 A1 12-07-2004 WO 0151050 A1 19-07-2001 US 2003118669 A1 26-06-2003 US 2003144306 A1 31-07-2003 2003215527 A1 US 20-11-2003 US 2004058018 A1 25-03-2004

PC., _. 2004/050493

				PC.,'2004/050493		004/050493
Patent do cited in sear		Publication date		Patent family member(s)		Publication date
US 2002	045646 A1		ZA AU WO	200205512 1907100 0026185	Α	10-02-2004 22-05-2000 11-05-2000
US 2004	028737 A1	12-02-2004	NONE			
EP 1222	922 A	17-07-2002	AU CA EP HU NO CN WO	7950200 2387746 1222922 0203333 20021875 1382049 0128559	A1 A1 A2 A T	30-04-2001 26-04-2001 17-07-2002 28-02-2003 04-06-2002 27-11-2002 26-04-2001
US 6299	904 B1	09-10-2001	AT AU CA CN DE DE ES WO JP TW US	209898 7451198 2286753 1130194 69802810 69802810 0996424 2164424 9853798 11043429 580397 2001009678	A A1 B D1 T2 A1 T3 A1 A	15-12-2001 30-12-1998 03-12-1998 10-12-2003 17-01-2002 18-04-2002 03-05-2000 16-02-2002 03-12-1998 16-02-1999 21-03-2004 26-07-2001
US 4786	505 A	22-11-1988	GSGRTTTUUANYDEEEEKPPPSSSIRRRKKKAAAACCCDDDDDDDDEEEEEFGGGKHK	2189698 154294 240250 84215 140387 184482 601974 7191287 1292693 87103284 1810 273197 3751860 3751860 3751860 3751860 3751860 3751860 3751860 3751860 3751860 3751860 3751860 3751860 3751860 3751860 3751860 3751860 3751860 3751860 3751860 3783394 247983 215887 0247983 0496437 0567201 2006457 2091971 2135443 871913 89300058 3007434 3020734 3032101 52897 135294	G A1 T T T B2 A C A A5 D1 T2 T1 A A2 A2 A2 T3 T3 A T1 T3 T3 A A T1 T3 T3 A	04-11-1987 17-03-1995 30-03-1990 15-01-1993 15-08-1996 15-10-1999 27-09-1990 05-11-1987 03-12-1991 11-11-1987 20-10-1995 08-11-1989 22-08-1996 21-11-1996 18-02-1993 06-05-1993 27-09-1990 31-10-1987 02-12-1987 29-07-1992 27-10-1993 01-01-1994 16-11-1996 01-11-1999 31-10-1987 22-06-1989 30-07-1993 30-07-1993 30-11-1996 31-03-2000 02-05-1997 09-12-1994

rmation on patent family members

PC1 2004/050493 Publication Patent document Patent family Publication cited in search report date member(s) date US 4786505 Α 31-10-1994 HR 920854 A1 HU 43954 A2 28-01-1988 ΙE 61416 B1 02-11-1994 JP 1863556 C 08-08-1994 JP 62258320 A 10-11-1987 JP 5069807 B 01-10-1993 JP 2740993 B2 15-04-1998 JP 5294831 A 09-11-1993 KR 9104579 B1 06-07-1991 25-07-1995 1683 A , B LT LV 10357 A ,B 20-02-1995 L۷ 20-12-1996 5760 A4 NO 871790 A ,B, 02-11-1987 NZ 26-04-1990 220096 A PH 18-09-1991 25701 A PL 265416 A1 21-07-1988 PT 84785 A ,B 01-05-1987 SI 8710681 A8 31-10-1996 SU 1820837 A3 07-06-1993 WO 9850019 Α ΑU 12-11-1998 7375598 A 27-11-1998 JP 2001524131 T 27-11-2001 TW 550090 B 01-09-2003 9850019 A1 WO 12-11-1998 US 05-07-2001 2001006649 A1 US 2003203018 A1 30-10-2003 WO 0078284 Α 28-12-2000 ΑU 5423200 A 09-01-2001 CA 2377605 A1 28-12-2000 EP 1187599 A1 20-03-2002 WO 0078284 A1 28-12-2000

Interr

ial Application No